PL176451B1 - Pochodne indolu, środek farmaceutyczny zawierający pochodne indolu i sposób wytwarzania pochodnych indolu - Google Patents

Pochodne indolu, środek farmaceutyczny zawierający pochodne indolu i sposób wytwarzania pochodnych indolu

Info

Publication number
PL176451B1
PL176451B1 PL93305554A PL30555493A PL176451B1 PL 176451 B1 PL176451 B1 PL 176451B1 PL 93305554 A PL93305554 A PL 93305554A PL 30555493 A PL30555493 A PL 30555493A PL 176451 B1 PL176451 B1 PL 176451B1
Authority
PL
Poland
Prior art keywords
group
formula
compound
ethenyl
ethyl
Prior art date
Application number
PL93305554A
Other languages
English (en)
Polish (pl)
Inventor
Alfredo Cugola
Giovanni Gavira
Simone Giacobbe
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of PL176451B1 publication Critical patent/PL176451B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
PL93305554A 1992-04-16 1993-04-15 Pochodne indolu, środek farmaceutyczny zawierający pochodne indolu i sposób wytwarzania pochodnych indolu PL176451B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds
PCT/EP1993/000938 WO1993021153A1 (en) 1992-04-16 1993-04-15 Indole-2-carboxylic acid derivatives

Publications (1)

Publication Number Publication Date
PL176451B1 true PL176451B1 (pl) 1999-05-31

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
PL93305554A PL176451B1 (pl) 1992-04-16 1993-04-15 Pochodne indolu, środek farmaceutyczny zawierający pochodne indolu i sposób wytwarzania pochodnych indolu

Country Status (41)

Country Link
US (4) US5374648A (enExample)
EP (1) EP0568136A1 (enExample)
JP (2) JPH0649027A (enExample)
KR (1) KR100264114B1 (enExample)
CN (1) CN1042331C (enExample)
AP (1) AP480A (enExample)
AT (1) AT403917B (enExample)
AU (1) AU666927B2 (enExample)
BE (1) BE1006343A5 (enExample)
BG (1) BG62136B1 (enExample)
BR (1) BR1100323A (enExample)
CA (3) CA2094073A1 (enExample)
CH (1) CH685630A5 (enExample)
CY (1) CY2038B1 (enExample)
CZ (1) CZ285799B6 (enExample)
DK (1) DK169890B1 (enExample)
ES (1) ES2105924B1 (enExample)
FI (1) FI106198B (enExample)
FR (1) FR2690919B1 (enExample)
GB (2) GB9208492D0 (enExample)
GE (1) GEP19991704B (enExample)
GR (1) GR1001619B (enExample)
HK (1) HK95797A (enExample)
HU (2) HU217964B (enExample)
IL (1) IL105412A (enExample)
IS (1) IS3994A (enExample)
IT (1) IT1265325B1 (enExample)
LU (1) LU88248A1 (enExample)
MX (1) MX9302195A (enExample)
MY (1) MY112232A (enExample)
NO (1) NO301879B1 (enExample)
NZ (1) NZ247413A (enExample)
OA (1) OA10103A (enExample)
PL (1) PL176451B1 (enExample)
RO (1) RO113242B1 (enExample)
RU (1) RU2129544C1 (enExample)
SE (1) SE504336C2 (enExample)
SK (1) SK281941B6 (enExample)
TW (1) TW224457B (enExample)
WO (1) WO1993021153A1 (enExample)
ZA (1) ZA932642B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
CN1051302C (zh) * 1993-05-27 2000-04-12 默里尔药物公司 3－(吲哚－3－基)丙烯酸衍生物及其用作nmda拮抗剂
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (enExample) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
IL129187A0 (en) * 1996-09-30 2000-02-17 Hoechst Marion Roussel Inc NMDA (N-methyl-D-aspartate) antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
PT2198858E (pt) * 1998-03-26 2011-09-01 Astellas Pharma Inc Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
HK1054231A1 (en) * 2000-07-31 2003-11-21 Dainippon Sumitomo Pharma Co., Ltd. Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
CA2468544A1 (en) * 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
EP1636240A1 (en) * 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
CN1922149A (zh) * 2003-12-29 2007-02-28 塞普拉科公司 吡咯和吡唑daao抑制剂
RU2281755C2 (ru) * 2004-04-19 2006-08-20 Пятигорская государственная фармацевтическая академия Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для ректального применения
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CA2614282A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP1976513B1 (en) 2006-01-06 2016-08-24 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
KR101381768B1 (ko) * 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
PT2816024T (pt) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
WO2008151156A1 (en) 2007-05-31 2008-12-11 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20110319463A1 (en) * 2009-03-10 2011-12-29 Saten Pharamaceuticals Co., Ltd. Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA2946153C (en) 2014-04-30 2022-06-14 Yufeng Jane Tseng Use of known compounds as d-amino acid oxidase inhibitors
CA3036250C (en) 2016-09-14 2023-09-26 Yufeng Jane Tseng Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
PT93943A (pt) * 1989-05-05 1991-02-08 Searle & Co Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
EP0539503B1 (en) * 1990-07-16 1996-04-03 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Also Published As

Publication number Publication date
FR2690919A1 (fr) 1993-11-12
ES2105924A1 (es) 1997-10-16
ZA932642B (en) 1994-01-10
IL105412A (en) 1998-02-22
HK95797A (en) 1997-08-08
HUT70526A (en) 1995-10-30
SE504336C2 (sv) 1997-01-13
US5374648A (en) 1994-12-20
GB2266091B (en) 1995-08-09
NO943913L (no) 1994-12-14
SK124194A3 (en) 1995-05-10
IL105412A0 (en) 1993-08-18
MX9302195A (es) 1994-03-31
JPH0649027A (ja) 1994-02-22
NO301879B1 (no) 1997-12-22
SE9301241D0 (sv) 1993-04-15
AP480A (en) 1996-03-22
GB9307808D0 (en) 1993-06-02
IT1265325B1 (it) 1996-10-31
IS3994A (is) 1993-10-17
OA10103A (en) 1996-12-18
AT403917B (de) 1998-06-25
EP0568136A1 (en) 1993-11-03
ES2105924B1 (es) 1998-07-01
FR2690919B1 (fr) 1995-05-05
CA2094076A1 (en) 1993-10-17
BE1006343A5 (fr) 1994-07-26
BG62136B1 (bg) 1999-03-31
CH685630A5 (fr) 1995-08-31
ITRM930236A1 (it) 1994-10-15
HU217964B (hu) 2000-05-28
CA2094075A1 (en) 1993-10-17
ATA75293A (de) 1997-11-15
DK169890B1 (da) 1995-03-27
US5373018A (en) 1994-12-13
AP9300524A0 (en) 1993-04-30
TW224457B (enExample) 1994-06-01
BG99111A (bg) 1995-05-31
GB9208492D0 (en) 1992-06-03
RU94045915A (ru) 1996-09-10
LU88248A1 (fr) 1994-03-01
CY2038B1 (en) 1998-04-30
FI944800A0 (fi) 1994-10-12
JPH07505407A (ja) 1995-06-15
WO1993021153A1 (en) 1993-10-28
CA2094073A1 (en) 1993-10-17
DK43193A (da) 1993-10-17
CZ254394A3 (en) 1995-07-12
GEP19991704B (en) 1999-08-05
FI106198B (fi) 2000-12-15
GB2266091A (en) 1993-10-20
DK43193D0 (da) 1993-04-15
BR1100323A (pt) 2000-06-27
SK281941B6 (sk) 2001-09-11
KR100264114B1 (ko) 2000-11-01
HU211826A9 (en) 1995-12-28
CN1085212A (zh) 1994-04-13
CN1042331C (zh) 1999-03-03
AU666927B2 (en) 1996-02-29
FI944800L (fi) 1994-10-12
NZ247413A (en) 1995-12-21
HU9402975D0 (en) 1995-02-28
AU3692393A (en) 1993-10-21
MY112232A (en) 2001-05-31
RO113242B1 (ro) 1998-05-29
US5374649A (en) 1994-12-20
GR1001619B (el) 1994-07-29
NO943913D0 (no) 1994-10-14
US5510367A (en) 1996-04-23
SE9301241L (sv) 1993-10-17
ITRM930236A0 (it) 1993-04-15
RU2129544C1 (ru) 1999-04-27
CZ285799B6 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
US5374648A (en) Indole derivatives and pharmaceutical use thereof
US5686461A (en) Indole derivatives
US5962496A (en) Indole derivatives as NMDA antagonists
US6124285A (en) Indole-2,3-dione-3-oxime derivatives
PL194532B1 (pl) Pochodne tetrahydrochinoliny jako antagoniści EAA
US5919811A (en) 3-Substituted-indole-2-carboxylic acid derivatives as excitatory amino acid antagonists
US5977136A (en) Tetrahydroquinolines as NMDA antagonists
KR20080063755A (ko) 염증성 장애 치료용 피리미딘 화합물
AU731394B2 (en) Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
EP0519353B1 (en) Indolizin derivatives, process for their preparation and pharmaceutical composition containing them